Alimentiv Inc.
Clinical trials sponsored by Alimentiv Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study aims to pinpoint fastest Crohn's symptom relief Results expected Sep 2026 (estimated)
- Blood test may end guesswork in Crohn's drug choice Results expected Jun 2027 (estimated)
- New drug aims to unblock Crohn's-Damaged intestines Results expected Sep 2027 (estimated)
-
Crohn's patients in remission may ditch daily pills, study hints
Disease control OngoingThis study looks at whether people with Crohn's disease who are in remission can safely stop taking aminosalicylate (5-ASA) medication without their condition getting worse. About 334 participants will either continue or stop their 5-ASA therapy and be followed for 2 years to see…
Phase 4 • Sponsor: Alimentiv Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New study aims to pinpoint fastest Crohn's symptom relief
Knowledge-focused OngoingThis study follows 300 adults with Crohn's disease who are starting standard treatments like vedolizumab or IL-23 blockers. Researchers will track how quickly patients feel improvements in pain, fatigue, and daily functioning using simple questionnaires. The goal is to better und…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Scientists track drug behavior in severe colitis patients
Knowledge-focused OngoingThis study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works,…
Sponsor: Alimentiv Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC